Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA Flare Group plenary

Susan J. Bartlett, Vivian P. Bykerk, Roxanne Cooksey, Ernest H. Choy, Rieke Alten, Robin Christensen, Daniel E. Furst, Francis Guillemin, Serena Halls, Sarah Hewlett, Amye L. Leong, Anne Lyddiatt, Lyn March, Pamela Montie, Ana-Maria Orbai, Christoph Pohl, Marieke Scholte Voshaar, Thasia G. Woodworth, Clifton Bingham

Research output: Contribution to journalArticle

Abstract

Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. Methods. Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. Results. Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged > 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. Conclusion. These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.

Original languageEnglish (US)
Pages (from-to)2185-2189
Number of pages5
JournalJournal of Rheumatology
Volume42
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Rheumatoid Arthritis
Self Care
Joint Diseases
Rheumatology
Observational Studies
Fatigue
Outcome Assessment (Health Care)
Physicians
Pain
Research

Keywords

  • Disease exacerbation
  • Flare
  • OMERACT
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set : Report of the OMERACT 2014 RA Flare Group plenary. / Bartlett, Susan J.; Bykerk, Vivian P.; Cooksey, Roxanne; Choy, Ernest H.; Alten, Rieke; Christensen, Robin; Furst, Daniel E.; Guillemin, Francis; Halls, Serena; Hewlett, Sarah; Leong, Amye L.; Lyddiatt, Anne; March, Lyn; Montie, Pamela; Orbai, Ana-Maria; Pohl, Christoph; Scholte Voshaar, Marieke; Woodworth, Thasia G.; Bingham, Clifton.

In: Journal of Rheumatology, Vol. 42, No. 11, 01.11.2015, p. 2185-2189.

Research output: Contribution to journalArticle

Bartlett, SJ, Bykerk, VP, Cooksey, R, Choy, EH, Alten, R, Christensen, R, Furst, DE, Guillemin, F, Halls, S, Hewlett, S, Leong, AL, Lyddiatt, A, March, L, Montie, P, Orbai, A-M, Pohl, C, Scholte Voshaar, M, Woodworth, TG & Bingham, C 2015, 'Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA Flare Group plenary', Journal of Rheumatology, vol. 42, no. 11, pp. 2185-2189. https://doi.org/10.3899/jrheum.141169
Bartlett, Susan J. ; Bykerk, Vivian P. ; Cooksey, Roxanne ; Choy, Ernest H. ; Alten, Rieke ; Christensen, Robin ; Furst, Daniel E. ; Guillemin, Francis ; Halls, Serena ; Hewlett, Sarah ; Leong, Amye L. ; Lyddiatt, Anne ; March, Lyn ; Montie, Pamela ; Orbai, Ana-Maria ; Pohl, Christoph ; Scholte Voshaar, Marieke ; Woodworth, Thasia G. ; Bingham, Clifton. / Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set : Report of the OMERACT 2014 RA Flare Group plenary. In: Journal of Rheumatology. 2015 ; Vol. 42, No. 11. pp. 2185-2189.
@article{87d8ddf839394e3aa8c16a88203956b2,
title = "Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA Flare Group plenary",
abstract = "Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. Methods. Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. Results. Flare data from 501 patients in an observational study indicated 39{\%} were in flare, with mean (SD) severity of 6.0 (2.6) and 55{\%} lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged > 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. Conclusion. These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.",
keywords = "Disease exacerbation, Flare, OMERACT, Rheumatoid arthritis",
author = "Bartlett, {Susan J.} and Bykerk, {Vivian P.} and Roxanne Cooksey and Choy, {Ernest H.} and Rieke Alten and Robin Christensen and Furst, {Daniel E.} and Francis Guillemin and Serena Halls and Sarah Hewlett and Leong, {Amye L.} and Anne Lyddiatt and Lyn March and Pamela Montie and Ana-Maria Orbai and Christoph Pohl and {Scholte Voshaar}, Marieke and Woodworth, {Thasia G.} and Clifton Bingham",
year = "2015",
month = "11",
day = "1",
doi = "10.3899/jrheum.141169",
language = "English (US)",
volume = "42",
pages = "2185--2189",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "11",

}

TY - JOUR

T1 - Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set

T2 - Report of the OMERACT 2014 RA Flare Group plenary

AU - Bartlett, Susan J.

AU - Bykerk, Vivian P.

AU - Cooksey, Roxanne

AU - Choy, Ernest H.

AU - Alten, Rieke

AU - Christensen, Robin

AU - Furst, Daniel E.

AU - Guillemin, Francis

AU - Halls, Serena

AU - Hewlett, Sarah

AU - Leong, Amye L.

AU - Lyddiatt, Anne

AU - March, Lyn

AU - Montie, Pamela

AU - Orbai, Ana-Maria

AU - Pohl, Christoph

AU - Scholte Voshaar, Marieke

AU - Woodworth, Thasia G.

AU - Bingham, Clifton

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. Methods. Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. Results. Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged > 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. Conclusion. These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.

AB - Objective. The Outcome Measures in Rheumatology (OMERACT) Rheumatoid Arthritis (RA) Flare Group was established to develop an approach to identify and measure RA flares. An overview of our OMERACT 2014 plenary is provided. Methods. Feasibility and validity of flare domains endorsed at OMERACT 11 (2012) were described based on initial data from 3 international studies collected using a common set of questions specific to RA flare. Mean flare frequency, severity, and duration data were presented, and domain scores were compared by flare status to examine known-groups validity. Breakout groups provided input for stiffness, self-management, contextual factors, and measurement considerations. Results. Flare data from 501 patients in an observational study indicated 39% were in flare, with mean (SD) severity of 6.0 (2.6) and 55% lasting > 14 days. Pain, physical function, fatigue, participation, and stiffness scores averaged > 2 times higher (2 of 11 points) in flaring individuals. Correlations between flare domains and corresponding legacy instruments were obtained: r = 0.46 to 0.93. A combined definition (patient report of flare and 28-joint Disease Activity Score increase) was evaluated in 2 other trials, with similar results. Breakout groups debated specific measurement issues. Conclusion. These data contribute initial evidence of feasibility and content validation of the OMERACT RA Flare Core Domain Set. Our research agenda for OMERACT 2016 includes establishing duration/intensity criteria and developing criteria to identify RA flares using existing disease activity measures. Ongoing work will also address discordance between patient and physician ratings, facilitate application of flare criteria to clinical care, elucidate the role of self-management, and finalize recommendations for RA flare measurement.

KW - Disease exacerbation

KW - Flare

KW - OMERACT

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84946606821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946606821&partnerID=8YFLogxK

U2 - 10.3899/jrheum.141169

DO - 10.3899/jrheum.141169

M3 - Article

C2 - 25684764

AN - SCOPUS:84946606821

VL - 42

SP - 2185

EP - 2189

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 11

ER -